Insider Selling: OrthoPediatrics Corp. (NASDAQ:KIDS) CEO Sells $164,573.20 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey sold 6,620 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

OrthoPediatrics Stock Performance

KIDS opened at $25.54 on Friday. The business’s 50-day simple moving average is $24.84 and its 200 day simple moving average is $25.53. OrthoPediatrics Corp. has a 52-week low of $21.02 and a 52-week high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market capitalization of $620.29 million, a PE ratio of -20.76 and a beta of 1.22.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The company had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same quarter in the prior year, the business posted ($0.23) EPS. As a group, sell-side analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KIDS. Wellington Management Group LLP grew its holdings in OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after purchasing an additional 178,078 shares during the period. Wasatch Advisors LP lifted its position in shares of OrthoPediatrics by 47.2% in the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock valued at $16,141,000 after buying an additional 223,217 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of OrthoPediatrics by 29.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after acquiring an additional 152,681 shares during the period. AWM Investment Company Inc. increased its holdings in shares of OrthoPediatrics by 14.8% during the 4th quarter. AWM Investment Company Inc. now owns 516,794 shares of the company’s stock worth $11,979,000 after acquiring an additional 66,779 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in OrthoPediatrics in the 4th quarter valued at $9,798,000. Institutional investors own 69.05% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Stifel Nicolaus cut their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Truist Financial decreased their price target on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.